GLP-1 receptor agonists (GLP-1 RAs) are rapidly reshaping the therapeutic landscape, with approximately 12% of the US population reporting use. In addition to established treatments for weight management and type 2 diabetes, GLP-1 RAs are under active investigation for prevention of adverse cardiovascular events and treatment of metabolic dysfunction-associated steatotic liver disease. As clinical applications expand, bioanalytical methods must evolve to support efficient and scalable analysis of multiple peptide therapeutics. We present a single method for analysis of semaglutide, tirzepatide, taspoglutide and exenatide from human blood plasma that uses solid-phase extraction (SPE) to minimize matrix effects.
